Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 7/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 5/20 | 0.53 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.53 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL149312 | 0.87 | RAB9A (0.62) | MAOANPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL148250 | 0.81 | LMNA (0.61) | MAOAKCNK3SMN1; SMN2KDM4EMTNR1A | |
| SCHEMBL3696476 | 0.78 | MAOA (0.64) | MAOAKDM4EMTNR1AMTNR1BKMT2A | |
| SCHEMBL154006 | 0.78 | RAB9A (0.63) | KCNK3NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL22616930 | 0.77 | MAOA (0.86) | MAOAKDM4EMTNR1AMTNR1BKMT2A | |
| Carbazole SCHEMBL27864756 | 0.76 | LMNA (0.69) | NPC1RAB9AKDM4EPKMKMT2A | |
| SCHEMBL7990375 | 0.76 | KDR (0.84) | GRM4HDAC6KDRKCNK3KCNK9 | |
| SCHEMBL14183004 | 0.74 | GRM4 (0.53) | GRM4HDAC6KDRKCNK3KCNK9 | |
| SCHEMBL22216946 | 0.74 | GRM4 (0.78) | GRM4HDAC6KDRKCNK3KCNK9 | |
| SCHEMBL6278943 | 0.74 | GRM4 (1.00) | GRM4HDAC6NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362065-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-8084620-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | GRM4 2447/4885HDAC6 477/4885MAOA 3150/4885 |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | GRM4 2447/4885HDAC6 477/4885MAOA 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.